Lazard Asset Management’s CytomX Therapeutics CTMX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $98K | Buy |
43,316
+42,500
| +5,208% | +$96.2K | ﹤0.01% | 1869 |
|
|
2025
Q1 | $0 | Sell |
816
-4,689
| -85% | – | ﹤0.01% | 2352 |
|
|
2024
Q4 | $5K | Sell |
5,505
-3,323
| -38% | -$3.02K | ﹤0.01% | 2129 |
|
|
2024
Q3 | $10K | Sell |
8,828
-9,653
| -52% | -$10.9K | ﹤0.01% | 2030 |
|
|
2024
Q2 | $22K | Buy |
18,481
+17,263
| +1,417% | +$20.6K | ﹤0.01% | 2012 |
|
|
2024
Q1 | $2K | Sell |
1,218
-33
| -3% | -$54 | ﹤0.01% | 1935 |
|
|
2023
Q4 | $1K | Buy |
+1,251
| New | +$1K | ﹤0.01% | 2193 |
|
|
2022
Q3 | – | Sell |
-15,186
| Closed | -$27K | – | 2359 |
|
|
2022
Q2 | $27K | Hold |
15,186
| – | – | ﹤0.01% | 2043 |
|
|
2022
Q1 | $40K | Buy |
+15,186
| New | +$40K | ﹤0.01% | 1844 |
|
|
2021
Q1 | – | Sell |
-8,292
| Closed | -$54K | – | 1878 |
|
|
2020
Q4 | $54K | Buy |
+8,292
| New | +$54K | ﹤0.01% | 1360 |
|
|
2020
Q3 | – | Sell |
-963
| Closed | -$8K | – | 1625 |
|
|
2020
Q2 | $8K | Sell |
963
-48,637
| -98% | -$404K | ﹤0.01% | 1504 |
|
|
2020
Q1 | $380K | Hold |
49,600
| – | – | ﹤0.01% | 830 |
|
|
2019
Q4 | $412K | Sell |
49,600
-1,600
| -3% | -$13.3K | ﹤0.01% | 828 |
|
|
2019
Q3 | $377K | Hold |
51,200
| – | – | ﹤0.01% | 852 |
|
|
2019
Q2 | $574K | Hold |
51,200
| – | – | ﹤0.01% | 922 |
|
|
2019
Q1 | $550K | Buy |
51,200
+12,000
| +31% | +$129K | ﹤0.01% | 905 |
|
|
2018
Q4 | $591K | Hold |
39,200
| – | – | ﹤0.01% | 780 |
|
|
2018
Q3 | $725K | Buy |
+39,200
| New | +$725K | ﹤0.01% | 787 |
|